On 22 August, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the sale of Lecanemab for the early stages of Alzheimer’s disease in the UK. This is a landmark event in the development of a potentially disease-modifying treatment for the leading cause of death in England and Wales.